Efficacy of KPL-301 for Subjects with Giant Cell Arteritis
This study is currently recruiting participants.
Primary Objective: The primary objective of this phase 2, randomized, double-blind placebo-controlled study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new onset or relapsing/refractory giant cell arteritis (GCA).
Principal Investigator: Ketna Parekh
Study Coordinator: Jonathan Barrett
Trial Website: https://clinicaltrials.gov/ct2/show/NCT03827018